Considerations when prescribing opioid agonist therapies for people living with HIV DOI
Adati Tarfa,

Audun J Lier,

Sheela Shenoi

et al.

Expert Review of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: 17(7), P. 549 - 564

Published: July 1, 2024

Introduction Medications for opioid use disorder (MOUD) include agonist therapies (OAT) (buprenorphine and methadone), antagonists (extended-release naltrexone). All forms of MOUD improve (OUD) HIV outcomes. However, the integration services OUD remains inadequate. Persistent barriers to accessing underscore immediate necessity addressing pharmacoequity in treatment persons with (PWH).

Language: Английский

Come back when you’re infected: pharmacy access to sterile syringes in an Arizona Secret Shopper Study, 2023 DOI Creative Commons
Danielle M. Russell, Beth E. Meyerson, Arlene Mahoney

et al.

Harm Reduction Journal, Journal Year: 2024, Volume and Issue: 21(1)

Published: Feb. 22, 2024

Pharmacies are critical healthcare partners in community efforts to eliminate bloodborne illnesses. Pharmacy sale of sterile syringes is central this effort.

Language: Английский

Citations

8
Considerations when prescribing opioid agonist therapies for people living with HIV DOI
Adati Tarfa,

Audun J Lier,

Sheela Shenoi

et al.

Expert Review of Clinical Pharmacology, Journal Year: 2024, Volume and Issue: 17(7), P. 549 - 564

Published: July 1, 2024

Introduction Medications for opioid use disorder (MOUD) include agonist therapies (OAT) (buprenorphine and methadone), antagonists (extended-release naltrexone). All forms of MOUD improve (OUD) HIV outcomes. However, the integration services OUD remains inadequate. Persistent barriers to accessing underscore immediate necessity addressing pharmacoequity in treatment persons with (PWH).

Language: Английский

Citations

0